Project Grant HT94252510765
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15260, USA
Similar Awards
- The University of Pittsburgh was awarded a $1,144,800 Project Grant by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "Overcoming Immunotherapy Resistance in Acral Melanoma." The three-year project, starting on September 1, 2025, and completing on August 31, 2028, aims to investigate innovative medical solutions to address this critical health challenge relevant to military personnel and the broader...
- The University of Pittsburgh has been awarded a $726,989 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to conduct research on "IMMUNOTHERAPEUTIC TARGETING OF SLC39A9 IN CDKN2A-LOW MELANOMA." The three-year award, commencing on September 15, 2025, aims to advance biomedical research to transform healthcare for military service members, veterans, and the broader public. The research project will investigate medical...
- This Project Grant award, worth $647,861.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Pittsburgh. The funding will support a 3-year research project evaluating the interplay between B-cells and T-cells within the tumor microenvironment of melanoma, and the impact on immune checkpoint blockade therapies. The University of Pittsburgh, a major recipient of federal biomedical research grants, will...
- The University of Pittsburgh has been awarded a $681,379 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to evaluate B-T cell cross talk within tertiary lymphoid structures in melanoma progression and immune checkpoint blockade. The award has a performance period from July 1, 2024 to June 30, 2027. This research project aims to enhance understanding of the immune processes involved in melanoma development and response to...
- This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,317,584 to the University of Alabama at Birmingham (UAB) to conduct research on macrophage-centric prognostic biomarkers for checkpoint blockade immunotherapy in melanoma. The research aims to transform healthcare for military service members, veterans, and the broader public by developing innovative medical solutions to address critical health challenges. The...
- The Department of Defense's Defense Health Agency awarded a $558,832 Project Grant to Tufts University School of Medicine under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2024. This grant will support research focused on "Targeting Differentiation Epitope in CD11b of Tumor-Associated Inflammatory Monocytes: A Novel Adjuvant Dendritic Cell Therapy Approach for Mucosal Melanoma." The research aims to develop an innovative dendritic cell-based...
- The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
- The Defense Health Agency has awarded a $657,263 project grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (d.b.a. DFCI) in Boston, MA. The award, effective September 1, 2024 through August 31, 2027, will support DATA-DRIVEN BIOMARKER-INFORMED DECISION ANALYTICS IN MELANOMA: IMPROVING EFFICACY AND REDUCING TOXICITY OF IMMUNE CHECKPOINT BLOCKADE. Through this grant, DFCI will conduct research to develop data-driven...
- The Department of Defense's Defense Health Agency awarded a $1,194,425 Project Grant to The Wistar Institute of Anatomy and Biology to support a 3-year research project titled "DEVELOPING RATIONAL APPROACHES FOR ACRAL MELANOMA" under the Military Medical Research and Development program (CFDA 12.420). The grant will fund basic, translational, and clinical research aimed at developing new treatments and advancing scientific understanding of acral melanoma, a rare form of skin cancer. As...
- The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...